Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14719429 | 0.81 | USP2 (0.42) | USP2SMN1; SMN2NR1H2ESR2GPR119 | |
| SCHEMBL31080015 | 0.80 | USP2 (0.50) | USP2SMN1; SMN2NR1H2ESR2GPR119 | |
| SCHEMBL13801225 | 0.80 | USP2 (0.50) | USP2SMN1; SMN2RECQLNR1H2ESR2 | |
| SCHEMBL14719212 | 0.77 | SCD5 (0.43) | GPR119KDM4EMAPK1 | |
| SCHEMBL14718457 | 0.74 | GPR119 (0.44) | USP2SMN1; SMN2NR1H2ESR2GPR119 | |
| SCHEMBL14732486 | 0.74 | USP2 (0.36) | USP2SMN1; SMN2NR1H2ESR2GPR119 | |
| SCHEMBL14719662 | 0.73 | GPR119 (0.44) | USP2SMN1; SMN2NR1H2ESR2GPR119 | |
| SCHEMBL120243 | 0.73 | USP2 (0.50) | USP2SMN1; SMN2NR1H2ESR2GPR119 | |
| SCHEMBL16224510 | 0.72 | USP2 (0.43) | USP2SMN1; SMN2NR1H2ESR2GPR119 | |
| SCHEMBL20984021 | 0.72 | USP2 (0.43) | USP2SMN1; SMN2NR1H2ESR2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053565-A1 | SUBSTITUTED 3-PIPERIDONE COMPOUNDS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053565-A1 | SUBSTITUTED 3-PIPERIDONE COMPOUNDS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053565-A1 | SUBSTITUTED 3-PIPERIDONE COMPOUNDS | HTR3C, NPEPPS, RAP2C | USP2 3442/4885SMN1; SMN2 1531/4885RECQL 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.